This page shows prior authorization criteria extracted from Aetna's published imaging guidelines. 175 matching coverage rules found for this procedure.
Abdominal Pain
Indication Code: AB-2.2
Abdominal Wall Mass
Indication Code: PEDAB-13.1
Abdominal Wall Mass
Indication Code: AB-13.1
Abnormal Liver Chemistries
Indication Code: AB-30.1
Acute Pancreatitis
Indication Code: PEDAB-34.1
Acute Pancreatitis
Indication Code: AB-33.1
Adrenal Gland Metastases
Indication Code: ONC-31.4
Adrenal Hormone Excess/Symptomatic Adrenal Lesions
Indication Code: AB-16.2
Adrenal Lesions
Indication Code: PEDAB-17
Adrenal Lesions
Indication Code: PEDAB-17
Adrenal Tumors – Initial Work-up/Staging
Indication Code: ONC-15.10
Adrenal Tumors – Restaging/Recurrence
Indication Code: ONC-15.11
Adrenal Tumors – Surveillance
Indication Code: ONC-15.12
Adrenocortical Carcinoma
Indication Code: ONC-15.13
Amenorrhea
Indication Code: PEDPV-4.1
Anal Carcinoma – Restaging/Recurrence
Indication Code: ONC-24.3
Anal Carcinoma – Surveillance
Indication Code: ONC-24.4
Asymptomatic Adrenal Cortical Lesions
Indication Code: AB-16.1
Asymptomatic Elevation of Pancreatic Enzymes
Indication Code: AB-33.4
Asymptomatic Hematuria
Indication Code: AB-39.2
Bilateral Wilms Tumor (BWT)
Indication Code: PEDONC-7.3
Biliary Disease
Indication Code: PEDAB-16.2
Bowel Obstruction
Indication Code: PEDAB-28.1
Bowel Obstruction
Indication Code: AB-20.1
Bronchopulmonary or Thymic Carcinoid – Initial Staging
Indication Code: ONC-15.6
Bronchopulmonary or Thymic Carcinoid – Restaging/Recurrence
Indication Code: ONC-15.7
Bronchopulmonary or Thymic Carcinoid – Surveillance
Indication Code: ONC-15.8
Cancers of External Genitalia – Initial Work-Up/Staging
Indication Code: ONC-24.6
Cancers of External Genitalia – Restaging/Recurrence
Indication Code: ONC-24.7
Cardiac Imaging in Transplants
Indication Code: CD-16
Celiac Disease
Indication Code: AB-24.1
CHF – Imaging
Indication Code: CD-9.1
Chronic Diarrhea (More than 30 Days)
Indication Code: AB-21.2
Chronic Liver Disease, Cirrhosis and Screening for HCC
Indication Code: AB-26.1
Chronic Pancreatitis
Indication Code: PEDAB-34.2
Chronic Pancreatitis
Indication Code: AB-33.2
Classical Hodgkin Lymphoma
Indication Code: ONC-28.2
Clear Cell Sarcoma of the Kidney (CCSK)
Indication Code: PEDONC-7.5
Colorectal Cancer – Initial Work-up/Staging
Indication Code: ONC-16.2
Colorectal Cancer – Restaging/Recurrence
Indication Code: ONC-16.3
Colorectal Cancer – Surveillance/Follow-up
Indication Code: ONC-16.4
Congenital Mesoblastic Nephroma (CMN)
Indication Code: PEDONC-7.7
Exocrine Pancreatic Insufficiency
Indication Code: AB-33.3
Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors
Indication Code: ONC-31.8
Familial Adenomatous Polyposis (FAP) and Related Conditions
Indication Code: PEDONC-2.7
Fatty Liver (Metabolic Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD)
Indication Code: AB-29.2
Fistulae
Indication Code: AB-48
Fistulae
Indication Code: AB-48
Flank Pain, Renal Stone
Indication Code: PEDAB-4
Flank Pain, Renal Stone
Indication Code: PEDAB-4
Gallbladder
Indication Code: AB-28.1
Gallbladder and Biliary Tumors – Initial Work-up/Staging
Indication Code: ONC-14.6
Gallbladder and Biliary Tumors – Restaging/Recurrence
Indication Code: ONC-14.7
Gallbladder and Biliary Tumors – Surveillance/Follow-up
Indication Code: ONC-14.8
Gastric Cancer – Restaging/Recurrence
Indication Code: ONC-14.10
Gastric Cancer – Surveillance/Follow-up
Indication Code: ONC-14.11
Gastrointestinal Stromal Tumor (GIST)
Indication Code: ONC-12.5
Gastrointestinal/Pancreatic Neuroendocrine Cancers – Initial Work-up/Staging
Indication Code: ONC-15.3
Gastrointestinal/Pancreatic Neuroendocrine Cancers – Restaging/Recurrence
Indication Code: ONC-15.4
Gastrointestinal/Pancreatic Neuroendocrine Cancers – Surveillance
Indication Code: ONC-15.5
Gastrointestinal/Pancreatic Neuroendocrine Cancers – Suspected/Diagnosis
Indication Code: ONC-15.2
Gaucher Disease (Storage Disorders)
Indication Code: PN-8.6
GI Bleeding
Indication Code: AB-22.1
Hemophagocytic Lymphohistiocytosis (HLH)
Indication Code: PEDONC-18.3
Hepatic Arteries and Veins
Indication Code: AB-43.1
Hepatoblastoma
Indication Code: PEDONC-11.2
Hepatocellular Carcinoma (HCC) – Initial Work-up/Staging
Indication Code: ONC-14.3
Hepatocellular Carcinoma (HCC) – Restaging/Recurrence
Indication Code: ONC-14.4
Hepatocellular Carcinoma (HCC) – Surveillance/Follow-up
Indication Code: ONC-14.5
Hereditary (Primary) Hemochromatosis (HH) and Other Iron Storage Diseases
Indication Code: AB-11.2
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Indication Code: PEDONC-2.16
Hereditary Paraganglioma-Pheochromocytoma (HPP) Syndromes
Indication Code: PEDONC-2.13
Histiocytic Disorders – General Considerations
Indication Code: PEDONC-18.1
Hydronephrosis
Indication Code: PEDAB-20
Hydronephrosis
Indication Code: PEDAB-20
Incidental Pancreatic Mass or Suspected Metastatic Disease to Pancreas
Indication Code: AB-31.2
Indeterminate Intra-Abdominal Mass
Indication Code: AB-13.2
Indeterminate Renal Lesion
Indication Code: PEDAB-19
Indeterminate Renal Lesion
Indication Code: PEDAB-19
Indeterminate Renal Lesion
Indication Code: AB-35.1
Indications for Cardiac MRI
Indication Code: PEDCD-9.3
Inflammatory Bowel Disease, Crohn Disease, or Ulcerative Colitis
Indication Code: PEDAB-9
Inflammatory Bowel Disease, Crohn Disease, or Ulcerative Colitis
Indication Code: PEDAB-9
Kidney Transplant, Pre-Transplant Imaging Studies
Indication Code: AB-42.5
Known IBD
Indication Code: AB-23.2
Langerhans Cell Histiocytosis (LCH)
Indication Code: PEDONC-18.2
Liver Elastography
Indication Code: AB-45
Liver Elastography
Indication Code: AB-45
Liver Lesion Characterization
Indication Code: PEDAB-15
Liver Lesion Characterization
Indication Code: PEDAB-15
Liver Lesion Characterization
Indication Code: AB-29.1
Liver Metastases and Liver-Directed Therapies
Indication Code: ONC-31.2
Liver Transplant, Living Donor Pre-Transplant Imaging (Donor Imaging)
Indication Code: AB-42.2
Liver Transplant, Post-Transplant Imaging
Indication Code: AB-42.3
Liver Transplant, Pre-Transplant
Indication Code: AB-42.1
Lower Urinary Tract Infection
Indication Code: AB-40.2
Lumbar and Lumbosacral Plexus
Indication Code: PN-5.1
LUMBAR Syndrome
Indication Code: PEDPVD-5.4
Malignant Rhabdoid Tumor of the Kidney (MRT) and Other Extracranial Sites
Indication Code: PEDONC-7.6
Monitoring After Fontan Procedure
Indication Code: AB-26.4
MR Enterography and Enteroclysis Coding Notes
Indication Code: AB-1.4
MR Imaging
Indication Code: AB-1.3
MRCP
Indication Code: AB-27.1
Multiple Endocrine Neoplasias (MEN)
Indication Code: PEDONC-2.8
Neuroblastoma – Initial Staging
Indication Code: PEDONC-6.3
Neuroblastoma – Surveillance Imaging (Risk Group Dependent)
Indication Code: PEDONC-6.5
Neuroblastoma – Treatment Response Imaging (Risk Group Dependent)
Indication Code: PEDONC-6.4
Neuromuscular Junction Disorders
Indication Code: PN-8.4
Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Indication Code: PEDONC-8.3
Ocular Melanoma
Indication Code: ONC-5.9
Other Renal Cell Cancer Predisposition Syndromes
Indication Code: PEDONC-2.17
Ovarian Cancer – Initial Work-Up/Staging
Indication Code: ONC-21.3
Ovarian Cancer – Restaging/Recurrence
Indication Code: ONC-21.4
Ovarian Cancer – Surveillance
Indication Code: ONC-21.5
Ovarian Cancer – Suspected/Diagnosis
Indication Code: ONC-21.2
Pancreatic Cancer – Initial Work-up/Staging
Indication Code: ONC-13.3
Pancreatic Cancer – Restaging/Recurrence
Indication Code: ONC-13.4
Pancreatic Cancer – Screening Studies for Pancreatic Cancer
Indication Code: ONC-13.1
Pancreatic Cancer – Surveillance/Follow-up
Indication Code: ONC-13.5
Pancreatic Cancer – Suspected/Diagnosis
Indication Code: ONC-13.2
Pancreatic Cystic Lesions
Indication Code: AB-31.1
Paraneoplastic Syndromes
Indication Code: ONC-30.3
Pediatric Abdomen Imaging Appropriate Clinical Evaluation and Conservative Treatment
Indication Code: PEDAB-1.2
Pediatric Abdomen Imaging Modality General Considerations
Indication Code: PEDAB-1.3
Pediatric ACC – Imaging
Indication Code: PEDONC-14.2
Pediatric Aggressive Mature B-Cell Non-Hodgkin Lymphomas (NHL)
Indication Code: PEDONC-5.3
Pediatric Germ Cell Tumors
Indication Code: PEDONC-10
Pediatric Germ Cell Tumors
Indication Code: PEDONC-10
Pediatric Hepatocellular Carcinoma (HCC)
Indication Code: PEDONC-11.3
Pediatric Hodgkin Lymphoma (HL)
Indication Code: PEDONC-5.2
Pediatric Liver Failure and Cirrhosis
Indication Code: PEDAB-16.1
Pediatric Pancreatic Carcinoma
Indication Code: PEDONC-11.4
Pediatric Renal Cell Carcinoma (RCC)
Indication Code: PEDONC-7.4
Polycystic Kidney Disease
Indication Code: PEDAB-21
Polycystic Kidney Disease
Indication Code: PEDAB-21
Polycystic Kidney Disease
Indication Code: AB-38.1
Polycystic Liver Disease
Indication Code: AB-29.3
Portal Hypertension
Indication Code: AB-26.3
Post-Transplant Imaging
Indication Code: PEDONC-20.2
Postoperative Pain within 60 Days Following Abdominal Surgery
Indication Code: PEDAB-11
Postoperative Pain within 60 Days Following Abdominal Surgery
Indication Code: PEDAB-11
Pre-operative Assessment for Robotic Kidney Surgery
Indication Code: AB-35.2
Pyelonephritis
Indication Code: AB-40.1
Renal Cell Cancer (RCC) – Initial Work-up/Staging
Indication Code: ONC-17.2
Renal Cell Cancer (RCC) – Surveillance
Indication Code: ONC-17.4
Retinoblastoma – Imaging
Indication Code: PEDONC-12.2
Retroperitoneal Fibrosis
Indication Code: AB-47.0
Right Lower Quadrant Pain
Indication Code: PEDAB-3
Right Lower Quadrant Pain
Indication Code: PEDAB-3
Right Upper Quadrant and Epigastric Pain
Indication Code: AB-2.3
Right Upper Quadrant Pain
Indication Code: PEDAB-8
Right Upper Quadrant Pain
Indication Code: PEDAB-8
Small Bowel Bleeding Suspected
Indication Code: AB-22.2
Small Bowel Cancer – Initial Work-up/Staging
Indication Code: ONC-16.5
Small Bowel Cancer – Restaging/Recurrence
Indication Code: ONC-16.6
Soft Tissue Sarcomas – Initial Work-up/Staging
Indication Code: ONC-12.2
Spleen
Indication Code: AB-34.1
Suspected IBD (Crohn’s Disease or Ulcerative Colitis)
Indication Code: AB-23.1
Suspected Renal/Ureteral Stone(s)
Indication Code: AB-4.1
Testicular, Ovarian and Extragonadal Germ Cell Tumors – General Considerations
Indication Code: ONC-20.0
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Initial Work-Up/Staging
Indication Code: ONC-20.1
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Restaging/Recurrence
Indication Code: ONC-20.2
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Surveillance
Indication Code: ONC-20.3
Thyroid Cancer – Initial Work-up/Staging
Indication Code: ONC-6.2
Thyroid Cancer – Restaging/Recurrence
Indication Code: ONC-6.3
Transfusion-Associated (Secondary) Hemochromatosis
Indication Code: PEDAB-18.2
Transitional Cell Cancer – Initial Work-up/Staging
Indication Code: ONC-18.2
Transitional Cell Cancer – Surveillance/Follow-up
Indication Code: ONC-18.4
Tuberous Sclerosis Complex (TSC)
Indication Code: PEDONC-2.9
Undescended Testis
Indication Code: PEDPV-11.1
Unexplained Weight Loss
Indication Code: ONC-30.2
Unilateral Wilms Tumor (UWT)
Indication Code: PEDONC-7.2
Upper Urinary Tract
Indication Code: PEDAB-5.1
Uterine Anomalies
Indication Code: PV-14.1
Von Hippel-Lindau Syndrome (VHL)
Indication Code: PEDONC-2.10
Standard prior authorization requests are typically processed within 3–5 business days. Urgent/expedited requests may be processed within 24–72 hours when clinically necessary.
Most plans allow 30–60 days to file a first-level appeal. Expedited appeals for urgent cases are typically processed within 72 hours.
⚠ MRI uses no ionizing radiation, which is an important clinical consideration when choosing between MRI and CT.